GLP-1 Ripple Effects Reach Big Food: $73B of Brand Value "At Risk," Lay's Most Exposed, Beverages the Relative Winners

GLP-1 Ripple Effects Reach Big Food: $73B of Brand Value "At Risk," Lay's Most Exposed, Beverages the Relative Winners

The food-and-beverage side of the GLP-1 story has moved from anecdote to quantified exposure. A Brand Finance analysis (reported by Food Dive) estimates $73 billion in global food brand value is at risk from GLP-1-driven consumption changes. The concentration is striking: "Lay's is the most exposed food brand to the phenomenon globally, with the report finding $6.8 billion of its $15.1 billion brand value at risk¹. PepsiCo's five major snack brands collectively have $14.1 billion in exposure." Confectionery/chocolate and savory snacks account for 53% of the at-risk value despite being just 30% of the brand value studied.

The consumption data underneath: Cornell University/Numerator research (via Flavorist's synthesis) finds GLP-1 households cut overall grocery spending ~6%, with a 10.1% decline in savory-snack spending; an earlier FAIR report found GLP-1 users eat ~700 fewer calories per day, cutting hardest on processed foods, sugar-sweetened beverages, refined grains, and beef. Food Dive quotes the structural framing: "The challenge is not that consumers will stop buying chocolate or crisps altogether, but that millions of everyday consumption decisions could become smaller, less frequent, or shift towards entirely different categories."

How Big Food is responding:

• Nestlé launched Vital Pursuit, a product line explicitly targeting GLP-1 users (portion size, protein, micronutrients).
• Danone introduced an Oikos yogurt drink aimed at GLP-1 users, emphasizing protein and muscle-mass maintenance.
• Conagra put "GLP-1 friendly" labels on selected Healthy Choice frozen meals.
• Ferrero — 11 months after closing the Kellogg acquisition — bought better-for-you oatmeal/granola brand Purely Elizabeth, diversifying toward the categories GLP-1 users still buy.

Not everyone loses. Brand Finance flags beverage brands as beneficiaries — Gatorade and Aquafina (PepsiCo), Minute Maid (Coca-Cola), and Monster — as consumers reallocate toward hydration and functional drinks. The New York Times (Sept 18, 2026) captures how broad the second-order effects now are: "Already, sales of alcohol, chips, ice cream and sodas have taken a hit from consumers on the medications. Sales of bras in larger sizes are falling."

Meaning: this corroborates the medtech pattern already documented on this topic (GLP-1 Obesity Drugs Fuel Plunge in Bariatric Surgery Rates, Creating Long-Term Uncertainty for Medtech) — GLP-1 adoption is a demand shock that propagates far beyond pharma. The snack complex's exposure is now quantified at brand level, and the strategic response (protein-fortified, portion-controlled, "GLP-1 friendly" lines plus M&A into better-for-you) is becoming a standard playbook. Watch for the food majors' Q3/Q4 earnings calls to start quantifying GLP-1 commentary the way bariatric-surgery volumes already have.